profit from every $100 of sales.
$0$100
Emergent BioSolutions
$5.79-1.70% today
-43.9% in 1 year
1-year low $4.451-year high $13.90
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $5.66 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Emergent BioSolutions sold, what it kept, and what it did with the cash.
Sales went from $1.08 billion in 2022 to $705 million in 2025, with $52.6 million of profit last year.
SalesProfit
Emergent BioSolutions handed back 16% of the cash it generated last year.
Buybacks $25M
Free cash flow 2025$157M
Bought back its own shares$25M
Paid as dividends–
Cash vs. debt$205M vs. $572M
Emergent BioSolutions vs. similar companies
Emergent BioSolutions grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Emergent BioSolutions | 5.7× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Emergent BioSolutions's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,076 | 1,023 | 1,014 | 705 | |
| 383 | 318 | 332 | 379 | |
| -163 | -202 | -82 | 112 | |
| -38 | -518 | 37 | 238 | |
| -212 | -761 | -191 | 53 | |
| -4.47 | -14.85 | -3.60 | 0.93 | |
| 35.6% | 31.0% | 32.8% | 53.7% | |
| -15.2% | -19.7% | -8.0% | 15.9% | |
| -19.7% | -74.3% | -18.8% | 7.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,166 | 1,823 | 1,390 | 1,319 |
| Cash | 643 | 112 | 100 | 205 |
| Total debt | 1,406 | 860 | 664 | 572 |
| Total liabilities | 1,779 | 1,174 | 907 | 796 |
| 1,388 | 649 | 483 | 523 | |
| 50 | 51 | 53 | 57 | |
| -5.1% | -33.7% | -5.0% | 10.3% | |
| -15.2% | -117.1% | -39.5% | 10.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -34 | -206 | 59 | 171 | |
| 116 | 52 | 23 | 14 | |
| -150 | -258 | 36 | 157 | |
| Dividends paid | – | – | – | – |
| 82 | 0 | 0 | 25 | |
| 45 | 23 | 18 | 16 |
Valuation
- 5.7×
- 11.1×
- –
- 0.9×
- 0.4×
- 1.9×
- 2.8×
- 52.7%
- 17.7%
- 0.0%
Profitability
- 53.7%
- 15.9%
- 7.5%
- 24.6%
- -14.9%
- -12.1%
- -1.6%
- -0.7%
- 6.1%
- 7.3%
Growth
- −13.1%
- –
- +338.0%
- –
- +0.0%
Financial health
- 2.5×
- 1.10
- 43.4%
- 1.3×
- 4.29
- 2.08
- 0.51
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 24%of 946
Top 33%of 872
Top 3%of 563
Bottom 7%of 868
Top 1%of 986
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 0.21 | -0.25 | +184.0% |
| Feb 26, 2026 | -0.43 | 0.11 | −490.9% |
| Oct 29, 2025 | 1.06 | -0.12 | +983.3% |
| Aug 6, 2025 | 0.16 | -0.26 | +161.5% |
| May 7, 2025 | 0.71 | 0.49 | +44.9% |
| Mar 3, 2025 | 0.05 | -0.35 | +114.3% |
| Nov 6, 2024 | 1.37 | 0.49 | +179.6% |
| Aug 6, 2024 | -2.32 | -0.97 | −139.2% |
News
Emergent outlines $600M-$645M 2026 revenue outlook while raising adjusted gross margin to 45%-47%Seeking Alpha · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
75Pass
Philip Fisher
55No pass
Peter Lynch
32No pass
Joel Greenblatt
60Pass
Charlie Munger
42No pass
Terry Smith
43No pass
Questions about Emergent BioSolutions
Is Emergent BioSolutions a good stock to buy?
A business with weak numbers, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Emergent BioSolutions AI analysis
What does Emergent BioSolutions do?
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. It is in Biotechnology.
Does Emergent BioSolutions pay a dividend?
No. Emergent BioSolutions does not pay a dividend at the moment; in 2025 it returned $24.9 million to shareholders by buying back its own shares.
Is Emergent BioSolutions stock halal?
No. Emergent BioSolutions does not pass our halal screen: its debt is 192% of its market value, at or above the 33% limit. How we check
How has Emergent BioSolutions stock done over the past year?
Down 43.9% over the past twelve months, to $5.79. It traded between $4.45 and $13.90 and is 58.3% below its high.
Who are Emergent BioSolutions's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Emergent BioSolutions's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.